Publications by authors named "Maria Grazia Marrazza"
Article Synopsis
- The study aimed to assess how biological treatments for rheumatoid arthritis (RA) could potentially improve blood sugar levels in patients who also have type 2 diabetes mellitus (2TDM).
- Researchers analyzed data from patients with active RA who were not responding to standard treatment and found significant improvements in inflammatory markers and HbA1c after starting treatment with various first-line biological DMARDs.
- Results suggested that starting a biological DMARD can improve glucose levels in 2TDM patients with RA, potentially due to reduced inflammation, with anti-IL6 drugs showing slightly better results in lowering HbA1c.
COVID-19 is causing a high influx of patients suffering from serious respiratory complications leading the necessity to find effective therapies. These patients seem to present with cytokine perturbation and high levels of IL6. Tocilizumab and sarilumab could be effective in this condition.
View Article and Find Full Text PDFUser preference for a portable syringe pump for iloprost infusion.
Patient Relat Outcome Meas
June 2015
Purpose: Administration of intravenous iloprost - a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy - requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient mobility is considerably restricted due to the size and fixity of traditional syringe pumps. The aim of this study was to evaluate the satisfaction level of patients and nurses, after the introduction of a new portable syringe pump (Infonde(®), Italfarmaco S.
View Article and Find Full Text PDF